ReviewEuropean radiology2013
Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines.
Review in European radiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 161 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
161 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Ultrasound evaluation of varicoceles: systematic literature review and rationale of the ESUR-SPIWG Guidelines and Recommendations.Journal of ultrasound · 2020Pooled it
- Strategies for Improved Intra-arterial Treatments Targeting Brain Tumors: a Systematic Review.Frontiers in oncology · 2020Pooled it
- Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis.AJNR. American journal of neuroradiology · 2016Guideline
- Acute abdominal and pelvic pain in pregnancy: ESUR recommendations.European radiology · 2013Guideline
- A Pharmacokinetics, Efficacy, and Safety Study of Gadoterate Meglumine in Pediatric Subjects Aged Younger Than 2 Years.Investigative radiology · 2018Trial
- Safety of gadobutrol in over 23,000 patients: the GARDIAN study, a global multicentre, prospective, non-interventional study.European radiology · 2017Trial
- Gadobutrol in Renally Impaired Patients: Results of the GRIP Study.Investigative radiology · 2017Trial
- Safety of Gadobutrol: Results From 42 Clinical Phase II to IV Studies and Postmarketing Surveillance After 29 Million Applications.Investigative radiology · 2016Trial
- Nephrogenic systemic fibrosis risk after liver magnetic resonance imaging with gadoxetate disodium in patients with moderate to severe renal impairment: results of a prospective, open-label, multicenter study.Investigative radiology · 2015Trial
- [Contrast agent strategies in elective oncological imaging].Radiologie (Heidelberg, Germany) · 2026Review
- Nitroxide-Based Contrast Agents for MRI Cancer Diagnostics: Progress, Limitations, and Perspectives.Molecules (Basel, Switzerland) · 2026Review
- Gadolinium Pollution-A Future Forward Perspective on Human and Environmental Impact.Magnetic resonance in medicine · 2026Review
- Usability of Amorphous Manganese Oxide for Assessing the Proteoglycan Content in Articular Cartilage.Magnetic resonance in chemistry : MRC · 2026Article
- Metabolic Gadolinium Labeling ofBiomaterials research · 2026Article
- Clinical MR Biomarkers.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026Review
- Gadolinium toxicity: mechanisms, clinical manifestations, and nanoparticle role.Archives of toxicology · 2025Review
- Current Status and Future Aspects of Gadolinium Oxide Nanoparticles as Positive Magnetic Resonance Imaging Contrast Agents.Nanomaterials (Basel, Switzerland) · 2025Review
- Cationic fluorinated micelles for cell labeling andScientific reports · 2024Article
- Assessment of myocardial injuries in ischaemic and non-ischaemic cardiomyopathies using magnetic resonance T1-rho mapping.European heart journal. Cardiovascular Imaging · 2024Article
- Rational Design of Magnetic Nanoparticles as TMolecules (Basel, Switzerland) · 2024Review
101 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo update the guidelines of the Contrast Media Safety Committee (CMSC) of the European Society of Urogenital Radiology (ESUR) on nephrogenic systemic fibrosis and gadolinium-based contrast media. AREAS COVERED: Topics reviewed include the history, clinical features and prevalence of nephrogenic systemic fibrosis and the current understanding of its pathophysiology. The risk factors for NSF are discussed and prophylactic measures are recommended. The stability of the different gadolinium-based contrast media and the potential long-term effects of gadolinium in the body have also been reviewed.
Indexed as
Identifiers
22865271What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.